



1 / 8

*FIG. 1**FIG. 2*

2 / 8

1 mg/kg dose




FIG. 3

3 / 8






FIG. 4

4 / 8

Plasma Levels of d₄-Domperidone in Dog Formulation Comparison

*FIG. 5**FIG. 6*

PLACEBO	ACTIVE
Medium chain triglycerides are dispensed in a suitable stainless steel container.	Medium chain triglycerides are dispensed in a suitable stainless steel container.
↓	↓
Butylated hydroxytoluene and butylated hydroxyanisole are weighed separately and transferred into the mixing vessel while mixing. Mixing is continued until all dissolved. MCT may be warmed to $35 \pm 5^{\circ}\text{C}$ to dissolve the BHA / BHT.	Butylated hydroxytoluene and butylated hydroxyanisole are weighed separately and transferred into the mixing vessel while mixing. Mixing is continued until all dissolved. MCT may be warmed to $35 \pm 5^{\circ}\text{C}$ to dissolve the BHA / BHT.
↓	↓
Pre-weighed Precirol ATO 5 is added to the MCT and mixed thoroughly using a bench top mixer (200-600 rpm) to achieve a homogenous suspension.	Pre-weighed Precirol ATO 5 is added to the MCT and mixed thoroughly using a bench top mixer (200-600 rpm) to achieve a homogenous suspension.
↓	↓
The final mixture should be homogenized for 15 ± 5 minutes to achieve a lump-free suspension.	The final mixture should be homogenized for 15 ± 5 minutes to achieve a lump-free suspension.
↓	↓
Once a homogenous suspension is achieved, the mixture is deaerated until it is free of air bubbles.	Pre-weighed d ₄ -domperidone is added to the suspension and mixed thoroughly using a bench top mixer (200-600 rpm) to achieve a homogenous suspension.
	↓
	Once a homogenous suspension is achieved, the mixture is deaerated until it is free of air bubbles. Collect a composite sample from middle of the medicine container for in-process assay testing.

FIG. 7




FIG. 8

7 / 8




FIG. 9




FIG. 10

8 / 8




FIG. 11




FIG. 12